Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

@article{174526,
        author = {Shreya Srivastava},
        title = {Epigenetic Modifiers: Key Players in Overcoming Cancer Resistance},
        journal = {International Journal of Innovative Research in Technology},
        year = {2025},
        volume = {11},
        number = {10},
        pages = {4241-4245},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=174526},
        abstract = {Cancer resistance remains a major challenge, reducing the effectiveness of chemotherapy, immunotherapy, and targeted therapies. Epigenetic modifications, like histone modifications and DNA methylation, regulate gene expression and contribute to tumor progression and drug resistance. Key epigenetic modifiers, including DNMTs, HDACs, KDMs, and PRMTs, have emerged as potential therapeutic targets. Epigenetic inhibitors, alone or in combination with conventional therapies, have shown promising outcomes in overcoming resistance and improving treatment outcomes. This review explores the role of epigenetic modifications in cancer resistance and highlights recent advancements in epigenetic-targeted therapies.},
        keywords = {Epigenetic Modifiers, Cancer Resistance, DNA Methylation, Histone Modifications, Tumor Microenvironment, Epigenetic Therapy},
        month = {March},
        }